Pre-clinical in vivo Models of Vascular Graft Coating in the Prevention of Vascular Graft Infection: A Systematic Review

Mufty, Hozan; Eynde, Jef Van den; Meuris, Bart; Metsemakers, Willem‐Jan; Wijngaerden, Eric Van; Vandendriessche, Thomas; Steenackers, Hans; Fourneau, Inge

doi:10.1016/j.ejvs.2021.02.054

Cited by 12 publications

(10 citation statements)

References 124 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Drug-eluting stents have been widely used for coronary artery disease 67 and antibiotic-coated grafts are under development to prevent infection of vascular grafts. 68 AL circuits coated with drugs that improve endothelial function or prevent fibrosis in the lungs could be created. Such an AL might have benefits for treating patients during both the acute and chronic phases of COVID-19-related lung failure.…”

Section: The Promise Of An Al For Covid-19–related Lung Failurementioning

confidence: 99%

Artificial Lungs for Lung Failure in the Era of COVID-19 Pandemic: Contemporary Review

Naito

Shigemura

2023

Transplantation

View full text Add to dashboard Cite

In patients with severe acute respiratory distress syndrome caused by coronavirus 2019 , mortality remains high despite optimal medical management. Extracorporeal membrane oxygenation (ECMO) has been widely used to support such patients. ECMO is not a perfect solution; however, there are several limitations and serious complications associated with ECMO use. Moreover, the overall short-term mortality rate of patients with COVID-19 supported by ECMO is high (~30%). Some patients who survive severe acute respiratory distress syndrome have chronic lung failure requiring oxygen supplementation, long-term mechanical ventilation, or ECMO support. Although lung transplant remains the most effective treatment for patients with end-stage lung failure from COVID-19, optimal patient selection and transplant timing for patients with COVID-19-related lung failure are not clear. Access to an artificial lung (AL) that can be used for long-term support as a bridge to transplant, bridge to recovery, or even destination therapy will become increasingly important. In this review, we discuss why the COVID-19 pandemic may drive progress in AL technology, challenges to AL implementation, and how some of these challenges might be overcome. PURPOSE OF THIS REVIEWGiven the circumstances caused by the COVID-19 pandemic worldwide, an artificial lung (AL) that is specifically designed for long-term use in patients with lung failure caused by COVID-19 will become increasingly important. Research on ALs for long-term use has been advancing rapidly; however, there are several obstacles that must be overcome to develop an AL for clinical use. Moreover, issues that are unique to COVID-19 must be overcome.

show abstract

Section: The Promise Of An Al For Covid-19–related Lung Failurementioning

confidence: 99%

Artificial Lungs for Lung Failure in the Era of COVID-19 Pandemic: Contemporary Review

Naito

Shigemura

2023

Transplantation

View full text Add to dashboard Cite

show abstract

“…Two recent well conducted reviews have been published on preclinical models evaluating vascular graft coating and silver grafts, 3 , 4 but no review has been conducted so far on the analysis performed in experimental models to assess vascular graft infectability and infection. This review was conducted to collect and summarise key features of infection and infectability assessment techniques in VGEI experimental models.…”

Section: Introductionmentioning

confidence: 99%

A Narrative Review of Experimental Assessment to Study Vascular Biomaterials Infections and Infectability

Pugès

M’Zali

Pereyre

et al. 2023

EJVES Vascular Forum

View full text Add to dashboard Cite

“…Vascular prostheses may be burdened by a series of complications mainly due to fabrication or biomaterial failure such as dilation, rupture, thrombosis, allergic foreign-body reaction, and infection. In particular, a vascular graft or endograft infection (VGEI) is a clinically important complication that may occur following VG surgery or VE procedures accompanied by high morbidity and mortality rates [22][23][24][25][26][27][28][29][30][31][32][33]. The incidence of thoracic aortic VGEI is around 6% and, with mortality rates that relate to the clinical presentation, around 75%.…”

Section: Introductionmentioning

confidence: 99%

Infection of Vascular Prostheses: A Comprehensive Review

et al. 2023

View full text Add to dashboard Cite

Vascular graft or endograft infection (VGEI) is a complex disease that complicates vascular-surgery and endovascular-surgery procedures and determines high morbidity and mortality. This review article provides the most updated general evidence on the pathogenesis, prevention, diagnosis, and treatment of VGEI. Several microorganisms are involved in VGEI development, but the most frequent one, responsible for over 75% of infections, is Staphylococcus aureus. Specific clinical, surgical, radiologic, and laboratory criteria are pivotal for the diagnosis of VGEI. Surgery and antimicrobial therapy are cornerstones in treatment for most patients with VGEI. For patients unfit for surgery, alternative treatment is available to improve the clinical course of VGEI.

show abstract

Pre-clinical in vivo Models of Vascular Graft Coating in the Prevention of Vascular Graft Infection: A Systematic Review

Cited by 12 publications

References 124 publications

Artificial Lungs for Lung Failure in the Era of COVID-19 Pandemic: Contemporary Review

Artificial Lungs for Lung Failure in the Era of COVID-19 Pandemic: Contemporary Review

A Narrative Review of Experimental Assessment to Study Vascular Biomaterials Infections and Infectability

Infection of Vascular Prostheses: A Comprehensive Review

Contact Info

Product

Resources

About